Dengue infection is caused by the dengue virus that belongs to the family Flaviviridae. It is generally self-limiting and rarely fatal.
There are 4 serotypes (DEN-1, DEN-2, DEN-3, DEN-4). Infection w/ dengue serotype confers lifetime protective immunity to that specific serotype; cross-protection for other serotypes is only short-term.
It is transmitted to humans through the bites of infected Aedes mosquitoes. It is primarily transmitted by female Aedes aegypti, a tropical and subtropical species.Humans & monkeys are the amplifying hosts after the mosquito bite.
After 4-10 days of incubation period, illness begins immediately.
The acute phase of illness lasts for 3-7 days, but the convalescent phase may be prolonged for a week and may be associated with weakness and depression especially in adults.

Dengue References

  1. Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev. 1998 Jul;11(3):480-496. PMID: 9665979
  2. Songco RS, Purugganan H, Carandang EH, et al. AdHoc Committee on Dengue Infections of the Philippine Pediatric Society. Guidelines for the diagnosis and treatment of dengue hemorrhagic fever/dengue shock syndrome. Quezon City, PH: Philippine Pediatric Society Inc; 1998
  3. Philippine Pediatric Society Inc. Handbook of infectious diseases. Quezon City, PH: Philippine Pediatric Society Inc; 2004
  4. World Health Organization (WHO); Special Programme for Research and Training in Tropical Disease (TDR). Dengue: Guidelines for diagnosis, treatment, prevention and control. WHO Press; 2009:25-106
  5. Malaria & Vector Borne Diseases Control Unit Disease Control Directorate Directorate General of Health Services Ministry of Health & Family Welfare & WHO Bangladesh. National guidelines for clinical management of dengue syndrome. 1st ed. Bangladesh: Disease Control Directorate of Directorate General of Health Services, Ministry of Health & Family Welfare of Government of Peoples Republic of Bangladesh; 2000.
  6. Gunn VL, Nechyba C, eds. The Harriet Lane handbook: a manual for pediatric house officers. 16th ed. St. Louis, MO: MD Consult LLC; 2002.
  7. MedWorm
  8. Centers for Disease Control and Prevention: Division of Vector-Borne Infectious Diseases. CDC Dengue Fever Homepage. CDC.
  9. Technical Working Group on the 2010 PPS Interim Guidelines on Fluid Management of DF/DHF. 2010 Interim guidelines on fluid management of dengue fever and dengue hemorrhagic fever. Feb 2011. Accessed 29 Nov 2011.
  10. Ministry of Health Singapore. Clinical Guidelines on dengue fever (DF)/dengue hemorrhagic fever (DHF). Ministry of Health Singapore. 2002.
  11. Shepherd S, Hinfey PB. Dengue fever. eMedicine. Apr 2006.
  12. Ministry of Health Malaysia. Clinical practice guidelines: dengue infection in adults. 2003.
  13. Tomashek, KM. Dengue fever and dengue hemorrhagic fever. CDC. Accessed 25 Oct 2012.
  14. Chapter of Paediatrics, Academy of Medicine of Malaysia. Consensus statement on the management of dengue infection in the paediatric population. Jan 2000.
  15. World Health Organization. Dengue haemorrhagic fever: diagnosis, treatment, prevention and control. 2nd ed. Geneva: World Health Organization. WHO. 1997.
  16. Centers for Disease Control and Prevention. Dengue laboratory guidance and diagnostic testing. CDC. Accessed 19 Oct 2012.
  17. World Health Organization Regional Office for Southeast Asia. Guidelines for treatment of dengue fever/dengue hemorrhagic fever in small hospitals. WHO. 1999.
  18. World Health Organization (WHO) and Special Programme for Research and Training in Tropical Diseases (TDR). Dengue: guidelines for diagnosis, treatment, prevention and control - new edition. WHO Web Site. 2009. Accessed 28 Nov 2011.
  19. Research Institute for Tropical Medicine Medical Department. Dengue. From: Management protocols of infectious and tropical diseases Volume one: Vector borne, zoonotic and other infectious diseases. Mar 2002
  20. National Institute of Communicable Diseases Delhi. Investigation & control of outbreaks: dengue fever & dengue hemorrhagic fever. Delhi: Directorate General of Health Services. 2001.
  21. World Health Organization Southeast Asia Regional Office. Regional guidelines on dengue/DHF prevention and control. WHO. 1999.
  22. Ministry of Health Malaysia. Management of dengue fever in children. Ministry of Health Malaysia Web Site. 2004. Accessed 19 Dec 2007.
  23. WHO Regional Office for South-East Asia. Comprehensive guidelines for prevention and control of dengue and dengue haemorrhagic fever. Revised and expanded edition 2011. World Health Organization.
  24. Guy B, Briand O, Lang J, et al. Development of the Sanofi Pasteur tetravalent dengue vaccine: one more step forward. Vaccine. 2015 Dec 10;33(50):7100-7111. doi: 10.1016/j.vaccine.2015.09.108. PMID: 26475445
  25. World Health Organization. Immunization, vaccines and biologicals. Dengue vaccine research. WHO. 14 Dec 2015. Accessed 12 Jan 2016.
  26. World Health Organization. Dengue and severe dengue. WHO. Apr 2017.
  27. World Health Organization. Dengue vaccine: WHO position paper, July 2016 - recommendations. Vaccine. 2017 Mar;35(9):1200-1201. doi: 10.1016/j.vaccine.2016.10.070. PMID: 28185744
  28. Centers for Disease Control and Prevention. CDC Yellow Book 2018. Health Information for International Travel. CDC. 2017.
  29. Philippine Pediatric Society, Pediatric Infectious Disease Society of the Philippines. 2017 PPS-PIDSP Clinical practice guidelines on dengue in children. Philippine Pediatric Society. Jul 2017. Accessed 04 Sep 2017.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
Diagnosis of heart diseases has abruptly and significantly decreased across the globe due to the coronavirus disease 2019 (COVID-19) pandemic, especially affecting poorer countries, reveals a study.
Roshini Claire Anthony, 01 Dec 2020

An evidence-based, multifaceted intervention aimed at reducing haemodialysis catheter-related bloodstream infections (HD-CRBSIs) failed to improve this outcome, results of the REDUCCTION* trial showed.

Pearl Toh, 19 hours ago
While it is well known that COVID-19 illness is associated with coagulopathy, the optimal anticoagulation strategy remains elusive, and two studies presented at the ASH 2020 Congress further add to the growing debate on the appropriate anticoagulant dose for hospitalized patients with COVID-19.